OA received Swissmedic approval in July 2021 for the treatment of individuals with 5q-associated SMA below age 2 years and a clinical diagnosis of SMA type 1 or SMA patients with no more than three SMN2 gene copies (https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/authorisations/new-medicines/zolgensma-infusionsloesung-onasemnogen-abeparvovec.html). The gene discussed is SMN2; the disease is spinal muscular atrophy, type 1.